Literature DB >> 19094831

Headache and hormone replacement therapy in the postmenopausal woman.

E Anne MacGregor1.   

Abstract

Headache and migraine are common symptoms of the menopause, often associated with irregular periods, hot flashes, and night sweats. Perimenopausal women should routinely be asked about headache and migraine, so that they can be offered appropriate advice. If attacks are infrequent, it may be sufficient to optimize acute treatment strategies. Lifestyle changes, alone or combined with a nonprescription treatment such as isoflavones, may be considered, although evidence of efficacy is limited. In women with migraine and more severe menopause symptoms, continuous hormone replacement therapy should be considered, using a nonoral route and the lowest dose effective in controlling symptoms. For women who have contraindications to estrogen therapy or do not wish to use it, compounds that inhibit serotonin reuptake, such as venlafaxine, fluoxetine, and paroxetine, have all shown efficacy for the control of hot flashes and prevention of migraine. Gabapentin is another nonhormonal option that has clinical trial evidence of effectiveness in treating hot flashes and reducing the frequency and severity of migraine attacks. Although clonidine is licensed in several countries for migraine prophylaxis and treatment of vasomotor symptoms, any benefit from treatment is often offset by adverse events. There is evidence that hysterectomy can increase the frequency of migraine and menopause symptoms, with added morbidity and risk of mortality. Therapy should regularly be evaluated to assess its ongoing need, as hormonal triggers are self-limiting and abate after menopause.

Entities:  

Year:  2009        PMID: 19094831     DOI: 10.1007/s11940-009-0002-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  47 in total

1.  Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration.

Authors:  B W Somerville
Journal:  Neurology       Date:  1975-03       Impact factor: 9.910

2.  Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study.

Authors:  Ronit Haimov-Kochman; Edyah Barak-Glantz; Revital Arbel; Miriam Leefsma; Amnon Brzezinski; Ariel Milwidsky; Drorith Hochner-Celnikier
Journal:  Menopause       Date:  2006 May-Jun       Impact factor: 2.953

3.  Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches.

Authors:  Rossella E Nappi; Grazia Sances; Arianna Sommacal; Silvia Detaddei; Fabio Facchinetti; Silvano Cristina; Franco Polatti; Giuseppe Nappi
Journal:  Menopause       Date:  2006 Sep-Oct       Impact factor: 2.953

4.  Migraine in a specialist menopause clinic.

Authors:  E A MacGregor; D Barnes
Journal:  Climacteric       Date:  1999-09       Impact factor: 3.005

5.  Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study.

Authors:  E A MacGregor; A Frith; J Ellis; L Aspinall; A Hackshaw
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

Review 6.  Progestogen intolerance and compliance with hormone replacement therapy in menopausal women.

Authors:  N Panay; J Studd
Journal:  Hum Reprod Update       Date:  1997 Mar-Apr       Impact factor: 15.610

7.  The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test.

Authors:  E M Lichten; J B Lichten; A Whitty; D Pieper
Journal:  Headache       Date:  1996-06       Impact factor: 5.887

8.  Predictability of exogenous hormone effect on subgroups of migraineurs.

Authors:  L Mueller
Journal:  Headache       Date:  2000-03       Impact factor: 5.887

9.  Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women.

Authors:  F Granella; G Sances; C Zanferrari; A Costa; E Martignoni; G C Manzoni
Journal:  Headache       Date:  1993 Jul-Aug       Impact factor: 5.887

10.  Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache.

Authors:  Vincent Martin; Suzanne Wernke; Karen Mandell; Willie Zoma; Judy Bean; Susan Pinney; James Liu; Nabih Ramadan; Robert Rebar
Journal:  Headache       Date:  2003-04       Impact factor: 5.887

View more
  5 in total

Review 1.  Identification of molecular genetic factors that influence migraine.

Authors:  Bridget H Maher; Lyn R Griffiths
Journal:  Mol Genet Genomics       Date:  2011-04-26       Impact factor: 3.291

2.  Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.

Authors:  Makoto Tanaka; Yoshitaka Hashimoto; Noboru Sekiya; Naoki Honda; Steve Deacon; Masanobu Yamamoto
Journal:  J Bone Miner Metab       Date:  2013-10-11       Impact factor: 2.626

Review 3.  Glucose-Related Traits and Risk of Migraine-A Potential Mechanism and Treatment Consideration.

Authors:  Md Rafiqul Islam; Dale R Nyholt
Journal:  Genes (Basel)       Date:  2022-04-22       Impact factor: 4.141

Review 4.  Migraine headache in perimenopausal and menopausal women.

Authors:  E Anne MacGregor
Journal:  Curr Pain Headache Rep       Date:  2009-10

Review 5.  The associations between migraine, unipolar psychiatric comorbidities, and stress-related disorders and the role of estrogen.

Authors:  B Lee Peterlin; Michael J Katsnelson; Anne H Calhoun
Journal:  Curr Pain Headache Rep       Date:  2009-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.